Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Neoadjuvant Therapy for Stage IB2/IIA1 Cervical Cancer
NCT07130240Phase 2Recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in Cervical Cancer (CC), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Started Aug 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07130240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07130240.